The CMPSR continues to provide a resource for high quality collection and analysis of pharmacokinetic specimens. However, the CMPSR has greatly expanded to include collection, processing and analysis of clinical specimens for translational/correlative and pharmacodynamic studies associated with the Center's clinical trials program. Additional objectives of the CMPSR are to: 1) Provide a resource for high-quality collection, processing and analysis of clinical specimens for pharmacokinetic and correlative studies;2) Develop translational components for investigator-initiated clinical trials;and 3) Identify and validate biomarkers and molecular signatures that are predictive of response to therapy and investigate drug activity, pharmacodynamic responses and mechanisms of acquired or innate resistance. Further, the CMPSR provides UC Davis clinical investigators a comprehensive resource for clinical trial protocol development, including standardized and/or trial-specific language for specimen collection, and development of correlative study scientific components. It also provides services for preclinical modeling and biologic investigations of novel agents and therapeutic combinations that can serve as rationale for study development. Resource personnel work closely with the CTSU and clinical trial investigators to incorporate comprehensive and meaningful correlative and pharmacokinetic components into each trial. Users of the CMPSR are primarily UC Davis Cancer Center clinical investigators developing clinical trials. The CMPSR involvement in a clinical trial may range from the collection and shipping of UCD patient blood specimens enrolled on a cooperative group study, to broader roles including development and implementation of specialized specimen collection procedures and novel assays, comprehensive molecular correlative analysis of trial specimens and preclinical in vitro or in vivo modeling to generate drug mechanism hypotheses that can be tested in the clinic. These efforts often include significant CMPSR input during trial protocol development. The CMPSR also services as a bridge between clinical investigators with other Shared Resources.
This resource handles biological specimens used to understand how cancer therapies work, how cancers can be detected, how the body processes drugs, and how various combinations of therapies can be more or less effective. The specimens and analytical studies are carried out in conjunction, for the most part, with cancer clinical trials. Its results are important to improving options for treating different types of cancers.
|Riess, Jonathan W; Gandara, David R; Frampton, Garrett M et al. (2018) Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol 13:1560-1568
|Withers, Sita S; Moore, Peter F; Chang, Hong et al. (2018) Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs. Dev Comp Immunol 87:64-74
|Zhang, Jin; Xu, Enshun; Ren, Cong et al. (2018) Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant p53 by Downregulating PTEN. Cancer Res 78:1511-1521
|Rowson-Hodel, A R; Wald, J H; Hatakeyama, J et al. (2018) Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer. Oncogene 37:197-207
|Wang, Minan; Yao, Li-Chin; Cheng, Mingshan et al. (2018) Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J 32:1537-1549
|York, D; Sproul, C D; Chikere, N et al. (2018) Expression and targeting of transcription factor ATF5 in dog gliomas. Vet Comp Oncol 16:102-107
|Fletcher, Kyle; Klosterman, Steven J; Derevnina, Lida et al. (2018) Comparative genomics of downy mildews reveals potential adaptations to biotrophy. BMC Genomics 19:851
|Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
|Yuan, Ye; He, Yixuan; Bo, Ruonan et al. (2018) A facile approach to fabricate self-assembled magnetic nanotheranostics for drug delivery and imaging. Nanoscale 10:21634-21639
|Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987
Showing the most recent 10 out of 836 publications